Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

被引：0
|
作者：
Maria C. Foss-Freitas
Baris Akinci
Adam Neidert
Victoria J. Bartlett
Eunju Hurh
Ewa Karwatowska-Prokopczuk
Elif A. Oral
机构：
[1] University of Michigan,Division of Metabolism, Endocrinology & Diabetes and Caswell Diabetes Institute
[2] Dokuz Eylul University,Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, Michigan Medicine
[3] Akcea Therapeutics,undefined
[4] Inc,undefined
[5] University of Michigan,undefined
[6] Caswell Diabetes Institute,undefined
来源：
Lipids in Health and Disease | / 20卷
关键词：
Familial partial lipodystrophy; Angiopoietin-like protein 3; Triglycerides; Mixed meal test; Adipose tissue insulin resistance; Vupanorsen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 16 条
  • [1] Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
    Foss-Freitas, Maria C.
    Akinci, Baris
    Neidert, Adam
    Bartlett, Victoria J.
    Hurh, Eunju
    Karwatowska-Prokopczuk, Ewa
    Oral, Elif A.
    LIPIDS IN HEALTH AND DISEASE, 2021, 20 (01)
  • [2] Selective Targeting of Angiopoietin-Like 3 (ANGPTL3) via the Second-Generation Antisense Oligonucleotide (ASO) ISIS-703802 (AKCEA-ANGPTL3-LRx) in Subjects with Familial Partial Lipodystrophy (FPLD)
    Foss-Freitas, Maria Cristina
    Akinci, Baris
    Neidert, Adam H.
    Hench, Rita P.
    Swaidan, Mario
    Oral, Elif A.
    DIABETES, 2020, 69
  • [3] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
    Tarugi, Patrizia
    Bertolini, Stefano
    Calandra, Sebastiano
    JOURNAL OF BIOMEDICAL RESEARCH, 2019, 33 (02): : 73 - 81
  • [4] Angiopoietin-like protein 3 (ANGPTL3) deficiency and familial combined hypolipidemia
    Patrizia Tarugi
    Stefano Bertolini
    Sebastiano Calandra
    TheJournalofBiomedicalResearch, 2019, 33 (02) : 73 - 81
  • [5] DEVELOPMENT OF A THERAPEUTIC VACCINE FOR DYSLIPIDEMIA AND RELATED DISEASES TARGETING ANGIOPOIETIN-LIKE PROTEIN 3 (ANGPTL3).
    Fukami, Hirotaka
    Morinaga, Jun
    Nakagami, Hironori
    Kuwabara, Takashige
    Morishita, Ryuichi
    Oike, Yuichi
    Mukoyama, Masashi
    JOURNAL OF HYPERTENSION, 2023, 41 : E270 - E271
  • [6] Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3)
    Ginsberg, Henry N.
    Goldberg, Ira J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2023, 43 (03) : 388 - 398
  • [7] RNAi inhibition of angiopoietin-like protein 3 (ANGPTL3) with ARO-ANG3 mimics the lipid and lipoprotein profile of familial combined hypolipidemia
    Watts, G. F.
    Schwabe, C.
    Scott, R.
    Gladding, P.
    Sullivan, D.
    Baker, J.
    Clifton, P.
    Hamilton, J.
    Given, B.
    San Martin, J.
    Melquist, S.
    Knowles, J. W.
    Goldberg, I
    Hegele, R.
    Ballantyne, C.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3331 - 3331
  • [8] SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY
    Gaudet, D.
    Gipe, D. A.
    Khoury, E.
    Pordy, R.
    Sasiela, W.
    Chan, K. C.
    ATHEROSCLEROSIS, 2016, 252 : E254 - E255
  • [9] SAFETY AND EFFICACY OF EVINACUMAB, A MONOCLONAL ANTIBODY TO ANGPTL3, IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: A SINGLE-ARM, OPEN-LABEL, PROOF-OF-CONCEPT STUDY
    Gaudet, Daniel
    Gipe, Daniel
    Hovingh, Kees
    Ahmad, Zahid
    Cuchel, Marina
    Shah, Prediman
    Chyu, Kuang-Yuh
    Pordy, Robert
    Sasiela, William
    Chan, Kuo-Chen
    Khoury, Etienne
    ATHEROSCLEROSIS, 2017, 263 : E9 - E9
  • [10] Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation
    Reeskamp, Laurens F.
    Tromp, Tycho R.
    Huijgen, Roeland
    Stroes, Erik S. G.
    Hovingh, G. Kees
    Grefhorst, Aldo
    ATHEROSCLEROSIS, 2020, 315 : 68 - 75
12